Hibercell, Inc.

Richard Huhn

Nandita Bose

Jeremy Graff

Nadine Ottoson

Mark Uhlik

Jamie Lowe

Ben Harrison

This disclosure provides, in one aspect, dosing strategies for soluble &#x3b2;-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble &#x3b2;-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-&#x3b2;-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-&#x3b2;-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.

Growing community of inventors

Saint Paul, MN, United States of America

Richard Huhn